| Novel and emerging drugs for rarer chronic lymphoid leukaemias. | |
| | |
MedLine Citation:
|
PMID: 22483155 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Rarer chronic lymphoid leukaemias represent a challenge to the clinicians due to the limited information on their pathogenesis, difficulties on setting up prospective clinical trials and to their refractoriness to drugs used in the most common form of chronic lymphocytic leukaemia (CLL). In this review all these issues are addressed in three B-cell leukaemias: B-cell prolymphocytic leukaemia (B-PLL), hairy cell leukaemia (HCL) and HCL-variant and three T-cell leukaemias: T-cell prolymphocytic leukaemia (T-PLL), T-cell large granular leukaemia (T-cell LGLL) and adult T-cell leukaemia lymphoma (ATLL). Data will be presented on the natural history, current therapies and emerging drugs potentially useful in the treatment of patients with these leukaemias. Emphasis is made on: 1- the novel agents targeting a variety of B and T-cell antigens expressed in the surface of the leukaemic cells; these are either unconjugated monoclonal antibodies (McAb) such as Rituximab (anti-CD20), the second and third generation of anti-CD20 McAbs, Alemtuzumab (anti-CD52), Siplizumab (anti-CD2), Daclizumab (anti-CD25) and KW-0761, an anti-chemokine receptor 4 (CCR4) or McAbs conjugated to toxins such as CD22 linked to the pseudomonas exotoxin or radiolabelled McAb; 2- the use of new purine nucleosides such as nelarabine and 3- agents targeting deregulated genes in the leukaemic cells from these diseases such as the Poly (ADP-ribose) polymerase (PARP) Olarapib in T-PLL with deregulation of the ataxia telangiectasia mutated (ATM) gene. Data of phase I and II clinical studies with these agents as well as the potential and current use of other drugs is outlined. |
| | |
Authors:
|
Estella Matutes |
Related Documents
:
|
22453975 - Stem cells and calcium signaling. 22712645 - Research on neurodegenerative diseases using induced pluripotent stem cells. 22862925 - (19)f mri tracer preserves in vitro and in vivo properties of hematopoietic stem cells. 22888995 - A novel allele hla-dpb1*136:01 identified in a german hematopoietic stem cell volunteer... 12428095 - Phosphorotioated oligonucleotides trigger synthesis of human coagulation serine proteases. 1691675 - Segregation of discrete gs alpha-mediated responses that accompany homologous or hetero... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-3 |
Journal Detail:
|
Title: Current cancer drug targets Volume: - ISSN: 1873-5576 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101094211 Medline TA: Curr Cancer Drug Targets Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Haemato-Oncology Department, Royal Marsden Hospital & Institute of Cancer Research 203 Fulham road, London SW3 6JJ, England. estella.matutes@icr.ac.uk. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Emerging therapies in chronic myeloid leukemia.
Next Document: Novel and emerging drugs for acute lymphoblastic leukemia.